UNSPSC 51312312: Diphenhydramine methylbromide

This classification denotes a histamine h1 antagonist, antiemetic, antitussive, and hypnotic with the molecular formula C18H24NO.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UJO67AO8YI, chemically known as ethylamine, n,n-dimethyl-2-(diphenylmethoxy)-, methylbromide but more generally known as diphenhydramine methylbromide, which bears US NIH Compound Identifier 35726. European Medicines Agency schedules Diphenhydramine methylbromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01771MIG.

UNSPSC 51312312 Diphenhydramine methylbromide is a Commodity code that in recent state and local procurement activity covers pharmaceutical products—primarily naloxone, generic multi-source pharmaceuticals, and over-the-counter medications—supplied through competitive bidding and cooperative purchasing mechanisms to support public health, emergency response, and employee health benefit programs. The issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances coordinating procurement across member jurisdictions. Work ranges from direct purchase of emergency medical countermeasures (naloxone and drug deactivation systems) by individual counties to large-scale cooperative sourcing of generic pharmaceuticals and OTC products through authorized wholesaler networks serving state agencies, local governments, and participating states.

Activity is geographically dispersed across Florida, Texas, Minnesota, and Oregon, with recent solicitations including Seminole County, Florida's IFB60459723LAS (posted June 30, 2026; due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year term with one-year renewal option; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026; due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be supplied through three authorized wholesalers and effective July 1, 2026. The MMCAP procurement emphasizes price competitiveness (75 percent of evaluation weight), cGMP and DSCSA compliance, established wholesaler relationships, and flexible pricing structures; the Seminole County bid requires e-Procurement submission, E-Verify verification, and drug-free workplace certification.